He Xiaoning
School
School of Pharmaceutical Science and Technology, Medical College
Professional Title
Associate professor
Discipline
Health and Pharmacy Administration
Contact Information
022-27401835
hexn@tju.edu.cn
Room 208, Building 24, Tianjin University
300072
Education Background
- 访问学生| McMaster University, Canada| Health Economics| 2016
- Doctoral degree| Tianjin University| Health and Pharmacy Administration| 2017
- Master’s Degree| Tianjin University| Health and Pharmacy Administration| 2014
- Bachelor’s Degree| Fuzhou University| Pharmaceutical Engineering| 2012
Research Interests
- Health Economics and Pharmacoeconomics
- Real-world Medical Data Analysis
- Health Policy Evaluation
- Distributional Cost-effectiveness Analysis and Health Equity
Professional Membership
- Committee Member and Secretary, Professional Committee of Pharmacoeconomics, Chinese Pharmaceutical Association (CPA)
- Standing Committee Member, Professional Committee of Pharmaceutical Economics, China Health Insurance Research Association (CHIRA)
- Committee Member, Professional Committee of Health Technology Economics Evaluation, Chinese Health Economics Association
- Committee Member, Professional Committee of Pharmacoeconomics, Chinese Research Hospital Association (CRHA)
- Member of the 5th Council, Tianjin Administration Society
- Committee Member and Secretary, Professional Committee of Pharmacoeconomics, Tianjin Pharmaceutical Association
Positions & Employments
-
2021.7-Now
School of Pharmaceutical Science and Technology | Tianjin University | Associate Professor -
2019.9-2020.3
School of Health And Related Research | Sheffield University, the UK -
2017.7-2021.9
School of Pharmaceutical Science and Technology | Tianjin University | Lecturer
Academic Achievements
- Papers
- [1] Retrospective Real-World Comparison of Adherence,Persistence, Health-Care Utilization, and Costs Among Biologics for Moderate-to-Severe Psoriasis in China
- [2] The Social Distribution of Quality-Adjusted Life Expectancy Among Social Deprivation Subgroups in China
-
- [3] Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib
- [4] Health inequality aversion in China：Public and decision-maker views
- [5] Development of the County-Level Social Deprivation Index 2020 and Its Association With Health Outcomes in China
- [6] Can DRG payment under global budget with price adjustment curb the soaring healthcare costs? Insights from China's reform and its underlying mechanism
- [7] Matching-adjusted indirect comparison and cost-effectiveness of mitoxantrone hydrochloride liposome versus Chidamide in relapsed or refractory peripheral T-cell lymphoma in China
- [8] Cost-effectiveness analysis of trilaciclib for reducing the incidence of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer in China
- [9] Enhancing the Interpretation of Continuous Outcomes and Subgroup Analyses in Systematic Reviews
- [10] Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis
- [11] Incorporating absolute effects to enrich interpretation of findings from meta-analyses
- [12] Differences between physician and patient preferences for cancer treatments: a systematic review
- [13] Policy Updates on Access to and Affordability of Innovative Medicines in China
- [14] China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population
- [15] Can case-based payment contain healthcare costs? - A curious case from China
- [16] How Do Treatment Preferences of Patients With Cancer Compare With Those of Oncologists and Family Members? Evidence From a Discrete Choice Experiment in China
- [17] Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
- [18] Eliciting SF-6Dv2 health state utilities using an anchored best-worst scaling technique
- [19] Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension
- [20] Differences in Lung Cancer Treatment Preferences Among Oncologists, Patients and Family Members
- [21] Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete Choice Experiment with a Duration Dimension
- [22] Do Discrete Choice Experiments Approaches Perform Better Than Time Trade-Off in Eliciting Health State Utilities? Evidence From SF-6Dv2 in China
- [23] Direct Medical Costs of Incident Complications in Patients with Newly-diagnosed Type 2 Diabetes in China
- [24] The long-term clinical benefits and economic costs associated with increased use of prophylaxis among patients with haemophilia A in China: Population-based predictions from 2018 to 2033
- [25] Impact of Optimal Medical Therapy at Discharge on One-year Direct Medical Costs for Chinese Patients with Acute Coronary Syndromes
- [26] Retrospective database analysis of cancer risk in patients with type 2 diabetes mellitus in China
- [27] Health economic assessment of Gd-EOB-DTPA MRI versus ECCM-MRI and multi-detector CT for diagnosis of hepatocellular carcinoma in China
- [28] Insulin adherence and persistence among Chinese patients with type 2 diabetes: A retrospective database analysis
- [29] Economic and humanistic burden of osteoarthritis: A systematic review of large sample studies
- [30] Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China